IP
CRVS icon

Intellectus Partners’s Corvus Pharmaceuticals CRVS Stock Holding History

Intellectus Partners’s Portfolio CRVS Stock Details CRVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-2,700
Closed -$11K – 221
2019
Q1 		$11K Buy
2,700
+500
+23% +$2.11K ﹤0.01% 340
2018
Q4 		$8K Sell
2,200
-250
-10% -$1.71K 0.01% 209
2018
Q3 		$21K Hold
2,450
– – 0.01% 429
2018
Q2 		$27K Hold
2,450
– – 0.01% 395
2018
Q1 		$28K Hold
2,450
– – 0.01% 396
2017
Q4 		$25K Buy
2,450
+2,360
+2,622% +$30.2K 0.01% 407
2017
Q3 		$1K Sell
90
-1,392
-94% -$19.3K ﹤0.01% 752
2017
Q2 		$18K Buy
+1,482
New +$15.8K 0.01% 524

Other funds holding CRVS

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
ASP
Adams Street Partners Chicago, Illinois $443M AUM 49.46% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
CI
Cowen Inc New York $1.39B AUM 60.14% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Intellectus Partners's CRVS Position: Q2 2019 in Review

Intellectus Partners sold out of Corvus Pharmaceuticals (CRVS) in Q2 2019, closing a stake of 2,700 shares — an estimated $11K sold.

Intellectus Partners first reported a position in CRVS in Q2 2017 and held it in 8 quarters. The position peaked at $28K in Q1 2018. 45 funds tracked by Wall St. Rank hold CRVS as of Q2 2019.

  • Intellectus Partners reported no remaining Corvus Pharmaceuticals position as of Q2 2019 after selling out during the quarter.
  • Intellectus Partners sold 2,700 Corvus Pharmaceuticals shares in Q2 2019, an estimated $11K.
  • Intellectus Partners first reported a position in Corvus Pharmaceuticals in Q2 2017 and held it in 8 quarters.
  • Intellectus Partners's Corvus Pharmaceuticals position peaked at $28K in Q1 2018.
  • 45 funds tracked by Wall St. Rank held Corvus Pharmaceuticals as of Q2 2019.

Based on Intellectus Partners's 13F filing for Q2 2019, filed 8 Aug 2019.